胸腺基质淋巴细胞生成素
医学
哮喘
免疫学
哮喘的病理生理学
单克隆抗体
耐受性
病理生理学
过敏
细胞因子
临床试验
不利影响
抗体
药理学
内科学
作者
Giancarlo Marone,Giuseppe Spadaro,Mariantonia Braile,Remo Poto,Gjada Criscuolo,Hadas Pahima,Stefania Loffredo,Francesca Levi‐Schaffer,Gilda Varricchi
标识
DOI:10.1080/13543784.2019.1672657
摘要
Introduction: Thymic stromal lymphopoietin (TSLP) is overexpressed in the airways of severe asthmatics and is an upstream cytokine that orchestrates inflammatory responses in asthma. TSLP exerts its effects by binding to a high affinity heteromeric receptor complex composed of TSLPR and IL-7Rα. An association of polymorphisms in TSLP with airway hyperresponsiveness, IgE, eosinophilia and asthma has been documented. TSLP has been implicated in asthma pathophysiology. Tezepelumab is a first-in-class human monoclonal antibody that binds to TSLP, thus inhibiting its interaction with TSLP receptor complex. Tezepelumab given as an add-on-therapy to patients with severe uncontrolled asthma has shown safety, tolerability and efficacy. Several trials are evaluating the long-term safety and the efficacy of tezepelumab in adults and adolescents with severe uncontrolled asthma.Areas covered: We provide an overview of the monoclonal antibody therapeutics market for severe uncontrolled asthma, examine the underlying pathophysiology that drives TSLP and discuss the use of tezepelumab for the treatment of severe uncontrolled asthma,Expert opinion: TSLP is a promising target for T2-high and perhaps some patients with T2-low asthma. The results of preliminary clinical trials are encouraging. Several unanswered questions concerning basic pathophysiological aspects of TSLP variants, the long-term safety and efficacy of tezepelumab with different phenotypes/endotypes of asthma should be addressed.
科研通智能强力驱动
Strongly Powered by AbleSci AI